COVER

SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Connecting Your Project to the Right Service Provider

Outsourcing formulation development and manufacturing can help drug developers address complex dosage forms, scale-up risks, regulatory demands, and accelerated timelines by connecting projects with CDMO partners that offer specialized expertise, integrated workflows, and scalable manufacturing support.

FEATURES

SPECIAL REPORT - Advancements in Respiratory Drug Delivery

Advances in inhaled drug delivery are improving how therapies reach the lungs, with innovations in formulations, devices, biologics, and digital tools helping expand treatment options for respiratory diseases.

EXECUTIVE INTERVIEW - Dr. Michalis Papadakis Founder & CEO Brainomix

Brainomix founder and CEO Dr. Michalis Papadakis discusses how AI-powered imaging is helping drug developers improve clinical trial design, identify meaningful treatment effects, and advance new therapies in stroke, pulmonary fibrosis, and other areas of unmet need.

CAR T CELL THERAPY - The Rise of Scalable Allogeneic CAR T: Shaping a New Era in Oncology

Allogeneic CAR T therapies are helping move oncology toward more scalable, off-the-shelf treatment models that could expand access, support earlier intervention, and bring advanced cell therapy closer to community cancer settings.

DRUG DELIVERY - Improved Prediction of Food Effect on Oral Absorption

Dissolution-permeation testing is helping drug developers better predict how food affects oral drug absorption by measuring both drug solubilization and membrane permeation, reducing the risk of misleading results from dissolution data alone.

DRUG-DEVICE COMBINATION PRODUCTS - Incorporating Self-Administered Drug-Device Combination Products Into Clinical Trials Can Bring Outsized Challenges & Outstanding Rewards

Self-administered drug-device combination products can bring major benefits to clinical trials, improving patient convenience, dosing consistency, compliance, and real-world insight, but they require careful early planning around usability, safety, regulatory requirements, compatibility, manufacturing, and scale-up.

DRUG DEVELOPMENT - Drug Combination Screening in Oncology: Advancing Predictive Strategies for Precision Drug Development

Drug combination screening is helping oncology developers identify synergistic drug pairs, connect response patterns to tumor biology, and support more predictive, biomarker-guided strategies for precision cancer treatment.

SINGLE B CELL ANTIBODY DISCOVERY - Improving Therapeutic Candidate Selection in Drug Development

Single B cell antibody discovery is helping improve therapeutic candidate selection by preserving native heavy- and light-chain pairing, accelerating sequence-defined screening, and enabling earlier identification of candidates with stronger specificity, function, and developability.

CHEMOENZYMATIC LIGATION - Enabling Scalable, Sustainable Oligonucleotide Manufacturing

Chemoenzymatic ligation offers a scalable, more sustainable path for oligonucleotide manufacturing by combining SPOS fragment production with enzymatic assembly to improve purity, reduce impurities, and support growing demand for nucleic acid therapeutics.

CONTROLLED RELEASE - Precision in Every Dose: Advancing Controlled Release for Small Molecule Therapeutics

Controlled release technologies are helping small molecule therapeutics deliver more consistent drug exposure, improve patient adherence, reduce dosing frequency, and support more precise treatment through advanced formulation and delivery strategies.